Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 20 of 90 for:    hidradenitis suppurativa

A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS) (NOVA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03628924
Recruitment Status : Active, not recruiting
First Posted : August 14, 2018
Last Update Posted : November 1, 2019
Sponsor:
Information provided by (Responsible Party):
Janssen Research & Development, LLC

Brief Summary:
The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab in adult participants with moderate to severe hidradenitis suppurativa (HS).

Condition or disease Intervention/treatment Phase
Hidradenitis Suppurativa Drug: Guselkumab dose 1 Drug: Guselkumab dose 2 Drug: Guselkumab dose 3 Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 184 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects With Moderate to Severe Hidradenitis Suppurativa
Actual Study Start Date : September 4, 2018
Estimated Primary Completion Date : August 10, 2020
Estimated Study Completion Date : October 29, 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Guselkumab

Arm Intervention/treatment
Experimental: Group 1: Guselkumab Regimen 1
Participants will receive guselkumab dose 1 administered Intravenously (IV) followed by guselkumab dose 2 administered subcutaneously.
Drug: Guselkumab dose 1
Participants will receive guselkumab dose 1 IV.
Other Name: CNTO 1959

Drug: Guselkumab dose 2
Participants will receive guselkumab dose 2 SC in Group 1, 2 and Group 3.
Other Name: CNTO 1959

Drug: Placebo
Participants will receive matched placebo SC and IV in group 1, 2 and 3 with an additional placebo SC dose in Group 3.

Experimental: Group 2: Guselkumab Regimen 2
Participants will receive guselkumab dose 2 subcutaneously.
Drug: Guselkumab dose 2
Participants will receive guselkumab dose 2 SC in Group 1, 2 and Group 3.
Other Name: CNTO 1959

Drug: Placebo
Participants will receive matched placebo SC and IV in group 1, 2 and 3 with an additional placebo SC dose in Group 3.

Experimental: Group 3: Placebo then Guselkumab
Participants will receive placebo IV and SC and an additional SC placebo dose at Week 12 then cross over at Week 16 to receive guselkumab dose 2 and dose 3 SC and placebo SC.
Drug: Guselkumab dose 2
Participants will receive guselkumab dose 2 SC in Group 1, 2 and Group 3.
Other Name: CNTO 1959

Drug: Guselkumab dose 3
Participants will receive guselkumab dose 3 SC in Group 3.
Other Name: CNTO 1959

Drug: Placebo
Participants will receive matched placebo SC and IV in group 1, 2 and 3 with an additional placebo SC dose in Group 3.




Primary Outcome Measures :
  1. Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16 [ Time Frame: At Week 16 ]
    HiSCR is defined as at least 50 percent (%) reduction in total abscess and inflammatory nodule (AN) count with no increase in abscess count and no increase in draining fistula count relative to baseline.


Secondary Outcome Measures :
  1. Change From Baseline in Participant's Total Abscess and Inflammatory Nodule (AN) Count at Week 16 [ Time Frame: Baseline and Week 16 ]
    Change from baseline in total AN count at Week 16 will be reported. Abscess and inflammatory nodule will be counted for the HS affected anatomical regions. The AN count is the sum of number of abscess and inflammatory nodules across anatomical regions.

  2. Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16 [ Time Frame: Baseline and Week 16 ]
    The DLQI is a dermatology-specific quality of life instrument designed to assess the impact of the disease on a participant's quality of life. It is a 10-item Patient-reported outcomes (PRO) questionnaire related to skin that evaluate over last Week: 1) how painful or itchy skin, 2) embarrassed or self conscious, 3) skin interfered during shopping or looking home or yard, 4) influenced the clothes, 5) during social or leisure activities, 6) during sports, 7) working or studying, 8) problem due to skin with partners or friends 9) sexual difficulties and 10) skin treatment to assess overall quality of life that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The DLQI produces a numeric score that can range from 0 to 30. A higher score indicates more severe disease.

  3. Change From Baseline in Hidradenitis Suppurativa (HS)-Related Pain Symptom Score in the Past 24 Hours Based on Hidradenitis Suppurativa Symptom Diary (HSSD) at Week 16 [ Time Frame: Baseline and Week 16 ]
    HSSD is a 7-item patient self-reported questionnaire that assesses 5 HS-related symptoms including pain, tenderness, hot skin feeling, odor, and itchiness. The participants are asked to rate the severity of each symptom on a 0 to 10 numerical rating scale, with 0 indicating no symptom experience and 10 indicating the worst possible symptom experience. Change from baseline in HS-related pain symptom score (ranging from 0 to 10) will be determined.

  4. Percentage of Participants Who Achieved at Least 50, 75, 90, and 100 Percent Reduction in Total Abscess and Inflammatory Nodule Count at Week 16 [ Time Frame: At Week 16 ]
    Percentage of participants achieving at least 50%, 75%, 90%, and 100% reduction in total AN count at Week 16 will be reported.

  5. Percentage of Participants Who Achieved an Abscess and Inflammatory Nodule Count of 1 and 2 at Week 16 [ Time Frame: At Week 16 ]
    Percentage of participants achieving an AN count of 1 and 2 at Week 16 will be reported.

  6. Percentage of Participants Who Achieved Complete Elimination of Abscesses at Week 16 in Participants With Abscesses at Baseline [ Time Frame: At Week 16 ]
    Percentage of participants who achieved complete elimination of abscesses at Week 16 in participants with abscesses at baseline will be reported.

  7. Change From Baseline in the Number of Abscesses at Week 16 [ Time Frame: Baseline and Week 16 ]
    Change from baseline in number of abscesses at Week 16 will be reported.

  8. Change From Baseline in HSSD Symptom Scale Score (Other Than Pain in the Past 24 Hours) at Week 16 [ Time Frame: Baseline and Week 16 ]
    HSSD is a 7-item patient self-reported questionnaire that assesses 5 HS-related symptoms including pain, tenderness, hot skin feeling, odor, and itchiness. The participants are asked to rate the severity of each symptom on a 0 to 10 numerical rating scale, with 0 indicating no symptom experience and 10 indicating the worst possible symptom experience. Change from baseline in each individual tenderness, hot skin feeling, odor and itchiness symptom score (rated on a scale of 0-10) will be determined.

  9. Change From Baseline in HSSD Total Symptom Score at Week 16 [ Time Frame: Baseline and Week 16 ]
    HSSD is a 7-item patient self-reported questionnaire that assesses 5 HS-related symptoms including pain, tenderness, hot skin feeling, odor, and itchiness. The participants are asked to rate the severity of each symptom on a 0 to 10 numerical rating scale, with 0 indicating no symptom experience and 10 indicating the worst possible symptom experience. All 5 symptoms have a recall period of the past 7 days, except for 2 additional questions on pain which evaluate current pain and pain in the past 24 hours. Each individual symptom scale score, ranging from 0-10 will be summarized. A total symptom score, which will also range from 0-10, will be derived by averaging the 5 individual scale scores that utilize the past 7-day recall period with higher score indicates more severe disease.

  10. Percentage of Participants Who Achieved Complete Elimination of Draining Fistulas at Week 16 in Participants With Draining Fistulas at Baseline [ Time Frame: At Week 16 ]
    Percentage of participants who achieved complete elimination of draining fistulas at Week 16 in participants with draining fistulas at baseline will be reported.

  11. Change From Baseline in Number of Draining Fistulas at Week 16 [ Time Frame: Baseline and Week 16 ]
    Change from baseline in number of draining fistulas at Week 16 will be reported.

  12. Percentage of Participants Who Achieved Complete Elimination of Inflammatory Nodules at Week 16 in Participants With Inflammatory Nodules at Baseline [ Time Frame: At Week 16 ]
    Percentage of participants who achieved complete elimination of inflammatory nodules at Week 16 in participants with inflammatory nodules at baseline will be reported.

  13. Change From Baseline in Number of Inflammatory Nodules at Week 16 [ Time Frame: Baseline and Week 16 ]
    Change from baseline in number of inflammatory nodules at Week 16 will be reported.

  14. Percentage of Participants With Hidradenitis Suppurativa -Investigator's Global Assessment (HS-IGA) Score of Inactive (0), Almost Inactive (1), or Mild Activity (2) and With at Least 2-Grade Improvement Relative to Baseline at Week 16 [ Time Frame: Baseline and Week 16 ]
    The HS-IGA documents the investigator's assessment of the participant's HS at a given timepoint. The anatomic region with the most severe HS activity at the baseline will be evaluated for erythema, drainage, and pain and/or tenderness to palpation for each participant. The participant's HS is assessed as inactive (0), almost inactive (1), mild activity (2), moderate activity (3), or severe activity (4). A higher score indicates more severe disease. Percentage of participants with HS-IGA score of inactive (0), almost inactive (1), or mild activity (2) and with at least 2-grade improvement relative to baseline at Week 16 will be determined.

  15. Percentage of Participants With HS-IGA Score of Inactive (0) or Almost Inactive (1) at Week 16 [ Time Frame: At Week 16 ]
    The HS-IGA documents the investigator's assessment of the participant's HS at a given timepoint. The anatomic region with the most severe HS activity at the baseline will be evaluated for erythema, drainage, and pain and/or tenderness to palpation for each participant. Among Participants With Score of Moderate activity (3) or Severe activity (4) at Baseline, the same anatomic site selected for evaluation at the baseline will be re-evaluated at Week 16. The participant's HS is assessed as inactive (0), almost inactive (1), mild activity (2), moderate activity (3), or severe activity (4). A higher score indicates more severe disease. Percentage of participants with HS-IGA score of inactive (0), almost inactive (1) at Week 16 among participants with HS-IGA score of moderate activity (3) or severe activity (4) at baseline will be determined.

  16. Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Total Scores at Week 16 [ Time Frame: Baseline and Week 16 ]
    The HADS has been developed to identify symptoms of anxiety and depression in hospitalized participants and in outpatients. It comprises 14 items, seven to assess anxiety (HADS-A), namely items 1, 3, 5, 7, 9, 11, and 13; and seven to assess depression (HADS-D), namely items 2, 4, 6, 8, 10, 12, and 14. Each item receives a score from 0 to 3 on a Likert Scale. The total score for each scale is obtained by adding the individual scores for each item, with the maximum score 21. The presence or absence of depression and anxiety will be defined, for each respective scale, based on the following cutoff values: HADS (anxiety): 0-8 equal to (=) no anxiety; greater than (>) 9 = anxiety; HADS (depression): 0-8 = no depression; >9 = depression.

  17. Change From Baseline in High-Sensitivity C-Reactive Protein (hs-CRP) at Week 16 [ Time Frame: Baseline and Week 16 ]
    Change from baseline in hs-CRP at Week 16 will be reported.

  18. Patient Global Impression of Change (PGIC) of Hidradenitis Suppurativa Severity at Week 16 [ Time Frame: At Week 16 ]
    The PGIC of HS Severity is a questionnaire that measures participants' perceived change (improvement or deterioration) in severity of their HS. Participants will rate how his/her HS has changed since the beginning of the study using a 7-point scale ranging from 1 which indicates "a lot better now" to 7 which indicates "a lot worse now" with a neutral center point 4 which indicates ("neither better nor worse"). Participants PGIC of HS Severity at Week 16 will be determined.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Have moderate to severe Hidradenitis Suppurativa (HS) for at least 1 year (365 days) prior to the baseline visit as determined by the investigator through participant interview and/or review of the medical history
  • Have HS lesions present in at least 2 distinct anatomic areas (examples include but are not limited to left and right axilla; or left axilla and left inguinocrural fold)
  • Had an inadequate response to an adequate course of appropriate oral antibiotics for treatment of HS (or demonstrated intolerance to, or had a contraindication to oral antibiotics for treatment of their HS) in the investigator's opinion
  • Have a total abscess and inflammatory nodule (AN) count of greater than or equal to (>=) 3 at the screening and baseline visit
  • Must agree to daily use (throughout the entirety of the study) of one of the following over-the-counter treatments to the body areas affected with HS lesions: either soap and water, or a topical antiseptic wash containing chlorhexidine gluconate, triclosan, or benzoyl peroxide, or a dilute bleach bath

Exclusion Criteria:

  • Any other active skin disease or condition (example, bacterial, fungal or viral infection) that could have interfered with assessment of HS
  • Has a draining fistula count of greater than (>) 20 at the baseline visit
  • Receipt of prescription topical therapies for the treatment of HS within 14 days prior to the baseline visit
  • Receipt of systemic non-biologic therapies for the treatment of HS less than (<) 4 Weeks prior to the baseline visit
  • Receipt of any oral antibiotic treatment for HS or inflammatory disorders within 4 Weeks prior to the baseline visit

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03628924


  Show 45 Study Locations
Sponsors and Collaborators
Janssen Research & Development, LLC
Investigators
Layout table for investigator information
Study Director: Janssen Research & Development, LLC Clinical Trial Janssen Research & Development, LLC

Layout table for additonal information
Responsible Party: Janssen Research & Development, LLC
ClinicalTrials.gov Identifier: NCT03628924     History of Changes
Other Study ID Numbers: CR108500
2018-001176-38 ( EudraCT Number )
CNTO1959HDS2001 ( Other Identifier: Janssen Research & Development, LLC )
First Posted: August 14, 2018    Key Record Dates
Last Update Posted: November 1, 2019
Last Verified: October 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hidradenitis Suppurativa
Hidradenitis
Sweat Gland Diseases
Skin Diseases
Skin Diseases, Bacterial
Bacterial Infections
Skin Diseases, Infectious
Infection
Suppuration
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs